Journal article
Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation
British journal of haematology, Vol.174(2), pp.235-248
07/01/2016
DOI: 10.1111/bjh.14046
PMCID: PMC4940282
PMID: 26989808
Abstract
For diffuse large B-cell lymphoma (DLBCL) patients progressing after autologous haematopoietic cell transplantation (autoHCT), allogeneic HCT (alloHCT) is often considered, although limited information is available to guide patient selection. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified 503 patients who underwent alloHCT after disease progression/relapse following a prior autoHCT. The 3-year probabilities of non-relapse mortality, progression/relapse, progression-free survival (PFS) and overall survival (OS) were 30, 38, 31 and 37% respectively. Factors associated with inferior PFS on multivariate analysis included Karnofsky performance status (KPS) <80, chemoresistance, autoHCT to alloHCT interval <1-year and myeloablative conditioning. Factors associated with worse OS on multivariate analysis included KPS<80, chemoresistance and myeloablative conditioning. Three adverse prognostic factors were used to construct a prognostic model for PFS, including KPS<80 (4 points), autoHCT to alloHCT interval <1-year (2 points) and chemoresistant disease at alloHCT (5 points). This CIBMTR prognostic model classified patients into four groups: low-risk (0 points), intermediate-risk (2-5 points), high-risk (6-9 points) or very high-risk (11 points), predicting 3-year PFS of 40, 32, 11 and 6%, respectively, with 3-year OS probabilities of 43, 39, 19 and 11% respectively. In conclusion, the CIBMTR prognostic model identifies a subgroup of DLBCL patients experiencing long-term survival with alloHCT after a failed prior autoHCT.
Details
- Title: Subtitle
- Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation
- Creators
- Timothy S. Fenske - Community Health Systems - Lutheran HospitalKwang W. Ahn - Medical College of WisconsinTara M. Graff - Hematology Oncology AssociatesAlyssa DiGilio - Medical College of WisconsinQaiser Bashir - The University of Texas MD Anderson Cancer CenterRammurti T. Kamble - Baylor College of MedicineErnesto Ayala - University of South FloridaUlrike Bacher - University Medical Center Hamburg-EppendorfJonathan E. Brammer - The University of Texas MD Anderson Cancer CenterMitchell Cairo - New York Medical CollegeAndy Chen - Oregon Health & Science UniversityYi-Bin Chen - Harvard UniversitySaurabh Chhabra - Medical University of South CarolinaAnita D'Souza - Medical College of WisconsinUmar Farooq - University of IowaCesar Freytes - South Texas Veterans Health Care SystemSiddhartha Ganguly - University of KansasMark Hertzberg - Prince of Wales HospitalDavid Inwards - Mayo Clinic Rochester, MNSamantha Jaglowski - The Ohio State UniversityMohamed A. Kharfan-Dabaja - University of South FloridaHillard M. Lazarus - Case Western Reserve UniversitySunita Nathan - Rush UniversityAttaphol Pawarode - University of MichiganMiguel-Angel Perales - Memorial Sloan Kettering Cancer CenterNishitha Reddy - Vanderbilt University Medical CenterSachiko Seo - Fred Hutch Cancer CenterAnna Sureda - Duran i Reynals HospitalSonali M. Smith - University of ChicagoMehdi Hamadani - Froedtert Hospital
- Resource Type
- Journal article
- Publication Details
- British journal of haematology, Vol.174(2), pp.235-248
- DOI
- 10.1111/bjh.14046
- PMID
- 26989808
- PMCID
- PMC4940282
- NLM abbreviation
- Br J Haematol
- ISSN
- 0007-1048
- eISSN
- 1365-2141
- Publisher
- Wiley
- Number of pages
- 14
- Grant note
- Gamida Cell Teva Joint Venture Ltd.; Teva Pharmaceutical Industries Swedish Orphan Biovitrum Actinium Pharmaceuticals Seattle Genetics Sigma-Tau Pharmaceuticals The Leukemia & Lymphoma Society; Leukemia and Lymphoma Society Tarix Pharmaceuticals 5U10HL069294 / NHLBI; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI) N00014-13-1-0039; N00014-14-1-0028 / Office of Naval Research Osiris Therapeutics, Inc. Millennium: The Takeda Oncology Co. Optum Healthcare Solutions, Inc. U24-CA076518 / Public Health Service Grant/Cooperative Agreement from the National Cancer Institute (NCI) P30CA008748 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) Teva Neuroscience, Inc.; Teva Pharmaceutical Industries Fresenius-Biotech North America, Inc. Medac GmbH Miltenyi Biotec, Inc. National Institute of Allergy and Infectious Diseases (NIAID); United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID) Fred Hutchinson Cancer Research Center Stemsoft Software, Inc. Wellpoint, Inc. Roswell Park Cancer Institute St. Baldrick's Foundation Amgen, Inc.; Amgen Gentium SpA National Marrow Donor Program The Medical College of Wisconsin; General Electric University of Minnesota; University of Minnesota System Genentech, Inc.; Roche Holding; Genentech Perkin Elmer, Inc. THERAKOS, Inc. Blue Cross and Blue Shield Association University of Utah U10HL069294 / NATIONAL HEART, LUNG, AND BLOOD INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI) Merck Co, Inc.; Merck & Company Health Research, Inc. Ariad Remedy Informatics Kiadis Pharma; Dexcel Pharma HistoGenetics, Inc. Soligenix, Inc. Genzyme Corporation; Sanofi-Aventis Chimerix, Inc. Incyte Corporation Celgene Corporation; Bristol-Myers Squibb StemCyte, A Global Cord Blood Therapeutics Co. Be the Match Foundation Jeff Gordon Children's Foundation Otsuka America Pharmaceutical, Inc.; Otsuka Pharmaceutical National Heart, Lung and Blood Institute (NHLBI); United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI) NCI; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) HHSH250201200016C / Health Resources and Services Administration (HRSA/DHHS); United States Department of Health & Human Services; United States Health Resources & Service Administration (HRSA) Onyx Pharmaceuticals GlaxoSmithKline Milliman USA, Inc. Allos Therapeutics, Inc. TerumoBCT Sanofi US
- Language
- English
- Date published
- 07/01/2016
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359563602771
Metrics
18 Record Views